ea0056ep101 | Pituitary and Neuroendocrinology | ECE2018
Splitaite Anna
, Tulabaite Kotryna
, Abraitiene Agne
, Zelnyte Gintare
Background: Dopamine agonists (DAs) are the primary treatment for both microprolactinomas and macroprolactinomas. Two medications are FDA approved for the medical treatment of prolactinomas: cabergoline and bromocriptine. Although bromocriptine is deemed a secondary option after cabergoline, its lower cost may be a consideration for some patients. The purpose of this study is to analyze patients treated with different DAs during 12 months period and to identify the unchangeabl...